1 / 12

Goldstraw et al. J Thorac Oncol 2007

Why should we want to screen ?. Survival ( years ). Goldstraw et al. J Thorac Oncol 2007. Why should we want to screen ?. Localised. Stage shift !. Regional spread. Distant spread. When diagnosis is based on symptoms. When diagnosis is based on screening.

jasper
Télécharger la présentation

Goldstraw et al. J Thorac Oncol 2007

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Whyshouldwewanttoscreen? Survival (years) Goldstraw et al. J ThoracOncol 2007

  2. Whyshouldwewanttoscreen? Localised Stage shift ! Regional spread Distantspread Whendiagnosisisbased on symptoms Whendiagnosisisbased on screening

  3. National lungscreeningtrial (NLST) • Inclusioncriteria • Age 55-74 years • Smoking history ≥30PY, activeorstoppedlessthan 15 yearsago • Exclusioncriteria • History of lungcancer • Other priorcancer in past 5 years • Chest CT lessthan 18 monthsago • Unexplainedweightloss (>15lb in pastyear) • Metallic implantsordevices in chestor back • Home oxygensupplementation • Pneumoniatreatedwithantibiotics in past 12 weeks Aberle et al. N Engl J Med 2011

  4. National lungscreeningtrial (NLST) • 53’454 subjectsrandomisedtoone of twogroups: • Low dose CT • Chest X-ray • 3 screening roundsatannualintervals • Non-calcifiednodules ≥4mm in CT oranysize in X-raywerereferredfordiagnosticwork-up • Primary outcome: lungcancerrelatedmortality Aberle et al. N Engl J Med 2011

  5. National lungscreeningtrial (NLST) Aberle et al. N Engl J Med 2011

  6. National lungscreeningtrial (NLST) Aberle et al. N Engl J Med 2011

  7. National lungscreeningtrial (NLST) Kovalchik et al. N Engl J Med 2013

  8. National lungscreeningtrial (NLST) Kovalchik et al. N Engl J Med 2013

  9. Lung cancer screening trials Boiselle, JAMA 2013

  10. Screening recommendations Boiselle, JAMA 2013

  11. Open issues • Isone positive trialenoughevidence? • Was thereoverdiagnosis in the NSLT? • Will otherpopulationsatriskoflungcancerbenefitfrom CT screening? • Screening of a large, at-riskpopulationpossible? • Howmanyscreeningrounds? • Costeffectiveness? • «sideeffects» ofscreening (i.e.radiationexposure)

  12. Conclusions • Lung cancer is a lethal disease associated with substantial medical and economic burden. • NLST: lung cancer screening may reduce mortality considerably. • Possible advantage of LDCT screening has to be balanced against the potential of inducing harm. • Many issues are not yet resolved: i.e. overdiagnosis, number of screening rounds, study population, cost-efficacy. • Further evidenceandinformationisneeded, beforelungcancerscreeningcanberecommended in Switzerland.

More Related